Carlyle, SK Capital Partners, and Beacon Parent Holdings have announced an extension to their tender offer for acquiring bluebird bio’s outstanding common stock. The deadline for this offer has been pushed to one minute after 11:59 p.m., New York City time, on April 18, 2025, as communicated by Beacon Merger Sub, Inc. This extension provides additional time to meet the necessary conditions, including obtaining regulatory approvals. The offer was previously set to expire on April 4, 2025.
Equiniti Trust Company, LLC, the depositary for the offer, reported that about 65,120 shares of bluebird common stock were tendered as of April 2, 2025. Shareholders who have already tendered their shares are not required to take further action due to this extension.
The offer is being conducted according to the terms laid out in the Offer to Purchase, dated March 7, 2025, and associated documents filed by Parent and Merger Sub with the SEC. Central to these conditions are the tendering of a majority of bluebird shares, various regulatory approvals, and standard closing conditions.
Founded in 2010, bluebird bio focuses on severe genetic diseases. Their work encompasses pioneering gene therapy models, achieving FDA approval for three therapies in under two years. bluebird bio combines scientific innovation with commercial application, supporting patients, providers, and payers through their developed solutions.
Carlyle, known for its global investment scope, manages $441 billion in assets and has a comprehensive approach across equity, credit, and investment solutions. SK Capital specializes in the life sciences, specialty materials, and ingredients sectors, managing roughly $9 billion in assets while overseeing operations in more than 200 plants across 30 countries.
This announcement does not constitute an offer to buy or sell securities of bluebird. It follows a Tender Offer Statement on Schedule TO, submitted by Parent and Merger Sub with the SEC. Related materials and bluebird’s response can be accessed via the SEC’s website or the respective company’s platforms.
Stakeholders and investors are encouraged to thoroughly review all related documents before making decisions concerning the tender offer.
